
Michael C Burger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5710863/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors. Clinical Cancer Research, 2021, 27, 2723-2733.	7.0	33
2	Local Anesthetic-Induced Central Nervous System Toxicity during Interscalene Brachial Plexus Block: A Case Series Study of Three Patients. Journal of Clinical Medicine, 2021, 10, 1013.	2.4	4
3	Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide. Cancers, 2021, 13, 3577.	3.7	12
4	Non-Invasive Measurement of Drug and 2-HG Signals Using 19F and 1H MR Spectroscopy in Brain Tumors Treated with the Mutant IDH1 Inhibitor BAY1436032. Cancers, 2020, 12, 3175.	3.7	8
5	AMPK activation protects astrocytes from hypoxia‑induced cell death. International Journal of Molecular Medicine, 2020, 45, 1385-1396.	4.0	9
6	Disruption of peroxisome proliferator–activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells. Journal of Biological Chemistry, 2019, 294, 3037-3050.	3.4	18
7	Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma. Journal of Neurochemistry, 2018, 144, 421-430.	3.9	8
8	Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases. Journal of Clinical Medicine, 2018, 7, 216.	2.4	7
9	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncology Letters, 2017, 14, 1141-1146.	1.8	58
10	Bevacizumab for Patients with Recurrent Multifocal Glioblastomas. International Journal of Molecular Sciences, 2017, 18, 2469.	4.1	12
11	Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. International Journal of Molecular Sciences, 2017, 18, 726.	4.1	7
12	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Journal of the National Cancer Institute, 2016, 108, .	6.3	282
13	Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival. Oncolmmunology, 2016, 5, e1119354.	4.6	151
14	Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. PLoS ONE, 2016, 11, e0155315.	2.5	18